|
answer text |
<p>The UK is committed to working with industry and international organisations to
facilitate expanded manufacturing of affordable COVID-19 vaccines at scale. UK funding
of £250 million to the Coalition for Epidemic Preparedness Innovations (CEPI), and
our £548 million contribution to the COVAX Advance Market Commitment (AMC), supported
vaccine development partnerships and procurement for global vaccines access respectively.
We welcome that COVAX has convened a Supply Chains and Manufacturing Taskforce to
identify immediate and longer-term actions for increasing the volume and security
of global vaccine supply.</p><p>Building vaccine manufacturing capacity is a long
term, capital intensive, and high-risk endeavour. The Foreign, Commonwealth and Development
Office (FCDO) is working with the African Union and international partners, such as
CEPI, Gavi, and the World Health Organisation (WHO), as well as development finance
institutions and the private sector to catalyse investments for vaccine manufacturing
in Africa. The UK contributed to the development of the AstraZeneca (AZ) vaccine.
AZ produces the vaccine at scale through global manufacturing partnerships, and provides
it at a non-profit price to low and middle-income countries.</p>
|
|